Clinical significance of von Willebrand factor determination in elderly patients with chronic heart failure complicated with lower extremity venous thrombosis

doi:10.3969/j.issn.1673-8640.2022.05.008

Abstract

Abstract: Objective To analyze the predictive value of von Willebrand factor（vWF） for venous thrombosis in elderly patients with chronic heart failure（CHF）. Methods A total of 96 elderly patients with CHF were enrolled. Among them,59 patients with CHF without lower extremity venous thrombosis were enrolled in disease control group,and 37 patients with chronic heart failure complicated with lower extremity venous thrombosis were enrolled in disease study group. Totally,50 healthy subjects over 60 years old during the same period were enrolled in healthy control group. The general clinical data were collected,and vWF activity,D-dimer and coagulation function related indexes were determined. Logistic regression analysis of influencing factors for venous thrombosis in patients with CHF was performed. The efficiency of plasma vWF activity on lower extremity venous thrombosis in elderly patients with CHF was evaluated by receiver operating characteristic（ROC） curve. Results The vWF activity was higher in disease research group than that in disease control group（P<0.05）. Logistic regression analysis showed that vWF activity was an independent risk factor for lower extremity venous thrombosis in patients with CHF. The diagnostic cut-off value of plasma vWF activity for CHF complicated with lower extremity venous thrombosis was 231.5%,the sensitivity was 78.6%,and the specificity was 82.6%. Conclusions Plasma vWF activity level has clinical value in assessing the risk of lower extremity venous thrombosis in elderly patients with CHF.

Key words: Von Willebrand factor, Chronic heart failure, Venous thrombosis, Elder

SONG Jinping, MA Jing, HUANG Guohong. Clinical significance of von Willebrand factor determination in elderly patients with chronic heart failure complicated with lower extremity venous thrombosis[J]. Laboratory Medicine, 2022, 37(5): 438-442.

Figures/Tables 5

References 16

[1]	周蕾, 高占强. 心力衰竭合并心房颤动患者凝血指标、生化指标与静脉血栓发生情况分析[J]. 实用临床医药杂志, 2020, 24(18):50-53.
[2]	常静, 师宾芬, 罗进光, 等. 冠心病合并心力衰竭患者上肢浅静脉血栓发生率横断面调查及影响因素分析[J]. 临床医学研究与实践, 2021, 6(10):38-40.
[3]	TANG L, WU Y Y, LIP G Y, et al. Heart failure and risk of venous thromboembolism:a systematic review and meta-analysis[J]. Lancet Haematol, 2016, 3(1):e30-e44. DOI URL
[4]	ZUCHI C, TRITTO I, CARLUCCIO E, et al. Role of endothelial dysfunction in heart failure[J]. Heart Fail Rev, 2020, 25(1):21-30. DOI URL
[5]	郭允, 王学工. 加味益气强心汤对心阳亏虚型慢性心衰患者心功能、血管内皮功能的影响[J]. 陕西中医, 2021, 42(4):456-458.
[6]	中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志, 2018, 2(4):196-225.
[7]	常淑平, 俎小华, 谢泞鲜. 心力衰竭病人vWF、VPO1、NT-proBNP水平与心力衰竭严重程度的相关性分析[J]. 中西医结合心脑血管病杂志, 2019, 17(18):2873-2875.
[8]	RAJPAL S, AHLUWALIA J, KUMAR N, et al. Elevated von Willebrand factor antigen levels are an independent risk factor for venous thromboembolism:first report from North India[J]. Indian J Hematol Blood Transfus, 2019, 35(3):489-495. DOI URL
[9]	FAN M, WANG X, PENG X, et al. Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events:a systematic review and meta-analysis[J]. BMC Cardiovasc Disord, 2020, 20(1):72. DOI URL
[10]	李昇鹏, 谢兴宇. 慢性心力衰竭患者凝血功能紊乱机制及血栓弹力图在其凝血功能监测中的应用价值探究[J]. 贵州医药, 2020, 44(6):863-865.
[11]	王乐见, 史春娟, 章希文. vWF、Ⅷ因子水平变化与易栓症患者静脉血栓发生率的关系[J]. 心脑血管病防治, 2017, 17(3):228-229.
[12]	闫彬, 陆士奇, 杜伟鹏, 等. 血管性血友病因子抗原及其活性检测对急性心肌梗死患者辅助诊断的临床价值[J]. 中国急救医学, 2020, 40(6):542-548.
[13]	赵国良, 李达, 冯振宇, 等. 冠心病稳定型心绞痛(阳虚脉阻证)病人NO、IL-1、IL-6、vWF水平与冠状动脉病变程度的相关性研究[J]. 中西医结合心脑血管病杂志, 2020, 18(2):216-218.
[14]	JENKINS P V, RAWLEY O, SMITH O P, et al. Elevated factor Ⅷ levels and risk of venous thrombosis[J]. Br J Haematol, 2012, 157(6):653-663. DOI URL
[15]	王本文, 周睿, 蒋煜, 等. 沙库巴曲缬沙坦联合卡维地洛治疗不同病因老年人慢性心力衰竭的有效性和安全性分析[J]. 中国现代医学杂志, 2022, 32(4):84-88.
[16]	TAQUETI V R, SOLOMON S D, SHAH A M, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction[J]. Eur Heart J, 2018, 39(10):840-849. DOI URL

组别	例数	年龄/岁	年龄分布/[例（%）]			心功能分级/[例（%）]
组别	例数	年龄/岁	60~69岁	70~79岁	>80岁	Ⅱ级	Ⅲ级	Ⅳ级
疾病对照组	59	72.31±7.89	17（28.81）	27（45.76）	15（25.42）	2（3.39）	21（35.59）	36（61.02）
疾病研究组	37	76.96±5.31	3（8.11）	25（67.56）	9（24.32）	2（5.41）	9（24.32）	26（70.27）
统计值		-1.327	8.339			3.507
P值		0.188	0.015			0.173

组别	例数	年龄/岁	年龄分布/[例（%）]			心功能分级/[例（%）]
组别	例数	年龄/岁	60~69岁	70~79岁	>80岁	Ⅱ级	Ⅲ级	Ⅳ级
疾病对照组	59	72.31±7.89	17（28.81）	27（45.76）	15（25.42）	2（3.39）	21（35.59）	36（61.02）
疾病研究组	37	76.96±5.31	3（8.11）	25（67.56）	9（24.32）	2（5.41）	9（24.32）	26（70.27）
统计值		-1.327	8.339			3.507
P值		0.188	0.015			0.173

组别	例数	血小板计数/ （×10¹²/L）	高敏C反应蛋白/（mg/L）	总胆固醇/ （mmol/L）	三酰甘油/ （mmol/L）	高密度脂蛋白胆固醇/（mmol/L）	低密度脂蛋白胆固醇/（mmol/L）
正常对照组	50	255.62±45.47	1.75±1.20	4.42±0.73	1.11±0.45	1.26±0.22	2.68±0.73
疾病对照组	59	201.74±57.26^*	6.69±5.10^*	3.24±0.82^*	1.06±0.44	0.85±0.22^*	1.94±0.66^*
疾病研究组	37	222.28±65.43^*	6.65±5.18^*	3.33±1.04^*	1.04±0.25	0.92±0.36^*	1.97±0.82^*
统计值		42.842	60.994	47.222	0.571	63.29	22.982
P值		0.000	0.000	0.000	0.450	0.000	0.000

组别	例数	血小板计数/ （×10¹²/L）	高敏C反应蛋白/（mg/L）	总胆固醇/ （mmol/L）	三酰甘油/ （mmol/L）	高密度脂蛋白胆固醇/（mmol/L）	低密度脂蛋白胆固醇/（mmol/L）
正常对照组	50	255.62±45.47	1.75±1.20	4.42±0.73	1.11±0.45	1.26±0.22	2.68±0.73
疾病对照组	59	201.74±57.26^*	6.69±5.10^*	3.24±0.82^*	1.06±0.44	0.85±0.22^*	1.94±0.66^*
疾病研究组	37	222.28±65.43^*	6.65±5.18^*	3.33±1.04^*	1.04±0.25	0.92±0.36^*	1.97±0.82^*
统计值		42.842	60.994	47.222	0.571	63.29	22.982
P值		0.000	0.000	0.000	0.450	0.000	0.000

组别	例数	纤维蛋白原/（g/L）	D-二聚体/（μg/L）	凝血因子Ⅷ/%	vWF/%	凝血酶Ⅲ/%	蛋白C/%	蛋白S/%
正常对照组	50	2.65±0.43	0.07±0.05	91.13±24.40	89.34±19.75	75.3±9.77	105.83±18.23	73.47±19.77
疾病对照组	59	3.70±1.06^*	0.98±0.65^*	228.13±93.78^*	201.08±100.94^*	77.54±9.02	97.42±22.09	86.43±26.39
疾病研究组	37	3.81±0.97^*	1.80±0.82^*#	258.15±65.43^*	300.59±95.08^*#	79.22±10.66	96.86±22.19	84.67±21.45
F值		41.03	57.66	95.36	121.33	1.832	0.024	0.358
P值		0.001	0.001	0.000	0.000	0.165	0.881	0.597